161 related articles for article (PubMed ID: 24152338)
1. In vitro and ex vivo evaluation of a multi-epitope heparinase vaccine for various malignancies.
Tang XD; Guo SL; Wang GZ; Li N; Wu YY; Fang DC; Fan YH; Yang SM
Cancer Sci; 2014 Jan; 105(1):9-17. PubMed ID: 24152338
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic T lymphocyte epitopes from human heparanase can elicit a potent anti-tumor immune response in mice.
Tang XD; Liang GP; Li C; Wan Y; Chen T; Chen L; Yu ST; Xiong Z; Fang DC; Wang GZ; Yang SM
Cancer Immunol Immunother; 2010 Jul; 59(7):1041-7. PubMed ID: 20182872
[TBL] [Abstract][Full Text] [Related]
3. HLA-A2-restricted cytotoxic T lymphocyte epitopes from human heparanase as novel targets for broad-spectrum tumor immunotherapy.
Chen T; Tang XD; Wan Y; Chen L; Yu ST; Xiong Z; Fang DC; Liang GP; Yang SM
Neoplasia; 2008 Sep; 10(9):977-86. PubMed ID: 18714399
[TBL] [Abstract][Full Text] [Related]
4. Multiple antigenic peptides of human heparanase elicit a much more potent immune response against tumors.
Wang GZ; Tang XD; Lü MH; Gao JH; Liang GP; Li N; Li CZ; Wu YY; Chen L; Cao YL; Fang DC; Yang SM
Cancer Prev Res (Phila); 2011 Aug; 4(8):1285-95. PubMed ID: 21505182
[TBL] [Abstract][Full Text] [Related]
5. Peptide FLNPDVLDI of heparanase is a novel HLA-A2-restricted CTL epitope and elicits potent immunological antitumor effects in vitro with an 8-branched design.
Zhang J; Yang J; Fan D; Tao H; Wang H; Yu T
Oncol Rep; 2013 May; 29(5):1955-61. PubMed ID: 23503586
[TBL] [Abstract][Full Text] [Related]
6. [Immune response of heparinase gene modified dendritic cell-based vaccine on gastric cancer cells].
Cai YG; Fang DC; Chen L; Wang DX; Luo YH; Tang XD; Chen T; Yang SM
Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(44):3122-7. PubMed ID: 17313764
[TBL] [Abstract][Full Text] [Related]
7. Multiple antigenic peptides based on H-2K(b)-restricted CTL epitopes from murine heparanase induce a potent antitumor immune response in vivo.
Tang XD; Wang GZ; Guo J; Lü MH; Li C; Li N; Chao YL; Li CZ; Wu YY; Hu CJ; Fang DC; Yang SM
Mol Cancer Ther; 2012 May; 11(5):1183-92. PubMed ID: 22442309
[TBL] [Abstract][Full Text] [Related]
8. Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells.
Smith HA; McNeel DG
J Immunother; 2011 Oct; 34(8):569-80. PubMed ID: 21904219
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effect of new multiple antigen peptide based on HLA-A0201-restricted CTL epitopes of human telomerase reverse transcriptase (hTERT).
Liao ZL; Tang XD; Lü MH; Wu YY; Cao YL; Fang DC; Yang SM; Guo H
Cancer Sci; 2012 Nov; 103(11):1920-8. PubMed ID: 22909416
[TBL] [Abstract][Full Text] [Related]
10. DNA fusion vaccines induce epitope-specific cytotoxic CD8(+) T cells against human leukemia-associated minor histocompatibility antigens.
Rice J; Dunn S; Piper K; Buchan SL; Moss PA; Stevenson FK
Cancer Res; 2006 May; 66(10):5436-42. PubMed ID: 16707472
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel HLA-A2-restricted cytotoxic T lymphocyte epitope from cancer-testis antigen PLAC1 in breast cancer.
Liu W; Zhai M; Wu Z; Qi Y; Wu Y; Dai C; Sun M; Li L; Gao Y
Amino Acids; 2012 Jun; 42(6):2257-65. PubMed ID: 21710262
[TBL] [Abstract][Full Text] [Related]
12. [Identification of a novel HLA-A2-restrictive CTL epitope of an ovary cancer-associated antigen OVA66].
Jin S; Wang Y; Wang SJ; Zhang HZ; Li MX; Chen Y; Ge HL
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Mar; 21(2):233-6, 242. PubMed ID: 15766414
[TBL] [Abstract][Full Text] [Related]
13. Identification of an HLA-A*0201-restrictive CTL epitope from MUC4 for applicable vaccine therapy.
Wu J; Wei J; Meng K; Chen J; Gao W; Zhang J; Xu Z; Miao Y
Immunopharmacol Immunotoxicol; 2009; 31(3):468-76. PubMed ID: 19555216
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of HLA-A*02-restricted Hantaan virus multiple-antigenic peptide for CD8
Ma Y; Tang K; Zhang Y; Zhang C; Zhang Y; Jin B; Ma Y
Virol J; 2020 Jan; 17(1):15. PubMed ID: 32005266
[TBL] [Abstract][Full Text] [Related]
15. Chimeric peptide containing both B and T cells epitope of tumor-associated antigen L6 enhances anti-tumor effects in HLA-A2 transgenic mice.
Lin SI; Huang MH; Chang YW; Chen IH; Roffler S; Chen BM; Sher YP; Liu SJ
Cancer Lett; 2016 Jul; 377(2):126-33. PubMed ID: 27130449
[TBL] [Abstract][Full Text] [Related]
16. Protective CD8
Ma Y; Tang K; Zhang Y; Zhang C; Cheng L; Zhang F; Zhuang R; Jin B; Zhang Y
Virol J; 2020 Oct; 17(1):146. PubMed ID: 33028368
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of antitumor immunity efficacy of epitope-based vaccine with B16 cell line coexpressing HLA-A2/H-2kb and CTL multiepitope in HLA transgenic mice.
Song S; Wang F; He X; He Y; Li D; Sun S
Vaccine; 2007 Jun; 25(25):4853-60. PubMed ID: 17418455
[TBL] [Abstract][Full Text] [Related]
18. Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders.
Bae J; Tai YT; Anderson KC; Munshi NC
Br J Haematol; 2011 Nov; 155(3):349-61. PubMed ID: 21902685
[TBL] [Abstract][Full Text] [Related]
19. Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen.
Rice J; Buchan S; Stevenson FK
J Immunol; 2002 Oct; 169(7):3908-13. PubMed ID: 12244189
[TBL] [Abstract][Full Text] [Related]
20. HLA-A2-Restricted Epitopes Identified from MTA1 Could Elicit Antigen-Specific Cytotoxic T Lymphocyte Response.
Wu Y; Zhai W; Zhou X; Wang Z; Lin Y; Ran L; Qi Y; Gao Y
J Immunol Res; 2018; 2018():2942679. PubMed ID: 30596107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
